2023 diagnosis coding specificity
Since this rule was implemented, we have received very few reports of audits denying claims using unspecified codes - until recently
2023 Q2 Advocacy Update
The Advocacy Council continues its work on important issues that affect the allergy specialty, allergy practices and allergists.
2023 – Advocacy Council Executive Director of Advocacy and Government Affairs
J. Allen Meadows, MD, FACAAI, has been appointed to the position of Executive Director of Advocacy and Government Affairs.
New JZ modifier implementation begins July 1
Medicare will require the use of the new JZ modifier for single-dose containers when there are no discarded amounts of a drug/biologic.
Medical Debt Collection
Good faith estimates and medical debt collection will likely impact your practice and your patients in 2023.
Subspecialty Loan Repayment Program
In FY 2024, the American Academy of Pediatrics, the College and other medical specialty societies support the request of $30 million for PSLRP.
How will the debt ceiling affect your practice?
After weeks of negotiations, President Biden and House Speaker Kevin McCarthy (R-CA) reached an agreement over Memorial Day weekend on a framework for raising …
CIGNA’s Modifier -25 Policy Delayed
This new policy would markedly increase allergists’ offices administrative burden and restrict the use of modifier 25 on E&M services.
Confirming diagnoses
The Advocacy Council regularly receives queries from members on how to correctly code. Many are common issues, including for coding unconfirmed diagnoses.
Medical Liability Insurance Increases
The AMA noted medical liability premiums between 2019 and 2022 have increased at a rate that hasn’t been observed in more than two decades.